.png)
NextGen Heme Summit
Aug 27–28, 2026
Denver, Colorado
Invitation Only
Where
Generations of Leaders Meet.
A three-day summit at the edge of hematologic oncology — where today's thought leaders come together with the next generation of
investigators, and the partners working alongside them, to shape what's next.
Dates
August 27–28, 2026
Welcome reception · Wed 26 Aug
Venue
Le Méridien Denver Downtown
1475 California Street · Colorado
Focus
Leukemias, MDS & MPN
AML · ALL · CML · CLL
01 — From the Co-Chairs
Thank you, Denver.
Co-Chair
Naval Daver, MD
MD Anderson Cancer Center
Co-Chair
Elias Jabbour, MD
MD Anderson Cancer Center
Thank you, Denver. Over two days, 35 faculty, the next generation of investigators, and the partners working alongside them came together for nine sessions and 38 talks on the science shaping leukemia, MDS, and MPN care. To everyone who presented, debated, or made the trip, thank you for making this year's meeting what it was.
Dr. Naval Daver · Dr. Elias Jabbour
Co-Chairs · NextGen Heme Summit
02 — Program at a Glance
Three days,one conversation.
27
August
Thursday
Day One
MDS · MPN · Targeted Therapies in AML · Frontline
Therapy in ALL · Chronic Leukemia
5 sessions · 3 symposia · Group dinner
28
August
Friday
Day Two
Future Directions in AML · R/R ALL · ALL
Personalized Therapy · Frontline AML with
Venetoclax
4 sessions · 3 symposia · Closing
03 — The Program
Nine sessions, in full.
Select a day · open any session to see talks, debates & speakers
Day 1
Thu · 27 Aug
Day 2
Fri · 28 Aug
All times shown in Mountain Time · subject to change
Expand all sessions
7:30 AM
Registration · Light breakfast on tables
8:00 AM
Welcome & Chair Remarks · Dr. Naval Daver & Dr. Elias Jabbour
01
Session 01 · 8:15 AM
MDS Updates & Case Discussions
MDS
Updates in lower-risk MDS management and upcoming drugs
MOFFITT CANCER CENTER
Update on high-risk MDS
MD Anderson Cancer Center
CASE
MDS case-based discussion
NORTHWESTERN MEDICINE
panel
Panel discussion
MODERATORS
02
Session 02 · 9:00 AM
MPN Updates & Case Discussions
MPN
Frontline treatment options for PV and ET
MD Anderson Cancer Center
Optimizing frontline therapy of MF
Moffitt Cancer Center
Management of post-JAK inhibitor MF
MD ANDERSON CANCER CENTER
CASE
Case presentation — MPN
MD Anderson Cancer Center
panel
Panel discussion
MODERATORS
10:00 AM
Sponsor Symposium 1
BPDCN in 2026: Diagnosis, Targeted Therapy, and the Path Forward
10:30 AM
Coffee Break
03
Session 03 · 10:45 AM
Targeted Therapies in AML — The Move Toward Combinations
AML
Are all menin inhibitors made equal? Resistance and selection
Roswell Park Comprehensive Cancer Center
Frontline menin inhibitors: ongoing trials and data
UNC
FLT3 inhibitors in AML: frontline approaches in younger and older patients
Penn Medicine
Incorporating venetoclax into frontline IC regimens: research or prime time?
MD Anderson Cancer Center
From bystander to target: the impact of RAS in AML
The Ohio State University
panel
Panel discussion
12:00 PM
Symposium 2 · Lunch
FLT3-Mutated Acute Leukemia: Case-Based Approaches to Frontline and Relapsed Disease
12:45 PM
Networking Lunch
04
Session 04 · 1:30 PM
Optimizing Frontline Therapy in ALL
ALL
Optimizing Ph-negative frontline therapy: less chemotherapy
MD Anderson Cancer Center
How I treat Ph-positive ALL
MD ANDERSON CANCER CENTER
How to tailor therapy according to MRD
UCSF Health
panel
Panel discussion
MODERATORS
2:30 PM
Sponsor Symposium 3
Fixed-Duration Therapy in Treatment-Naïve CLL: The Evolving Role of uMRD as a Clinical Endpoint
05
Session 05 · 3:00 PM
Chronic Leukemia
CML / CLL
CML updates and future directions
MD Anderson Cancer Center
CASE
MDS case-based discussion
MD Anderson Cancer Center
How to optimize frontline therapy in CLL
MD ANDERSON CANCER CENTER
Treatment of R/R CLL
Fred Hutchinson Cancer Center
CASE
MDS case-based discussion
MD Anderson Cancer Center
panel
Panel discussion
MODERATORS
4:15 PM
Day 1 Wrap & Chair Remarks · Dr. Naval Daver & Dr. Elias Jabbour
Evening 6:00 PM - 9:00 PM
Group Dinner · Faculty and partners
8:00 AM
Arrival · Coffee and light breakfast
9:00 AM
Day 2 Chair Remarks · Dr. Naval Daver & Dr. Elias Jabbour
06
Session 06 · 9:15 AM
Future Directions in AML Therapy
AML
CD123 and CD33 targeting in AML: bench to bedside
MOFFITT CANCER CENTER
MRD as endpoint and MRD-based therapies in AML: myth or reality?
MD ANDERSON CANCER CENTER
Using FLT3 MRD to guide treatment in FLT3-mutated AML
Fralin Biomedical Research Institute, VTC
Immune and inflammatory drivers of AML: therapeutic opportunities
MD ANDERSON CANCER CENTER
CASE
MDS case-based discussion
Huntsman Cancer Institute
panel
Panel discussion
10:15 AM
Sponsor Symposium 4
Menin Inhibition in Acute Leukemias: Emerging Data, Resistance Mechanisms, and Rational Combinations
10:45 AM
Coffee Break
07
Session 07 · 11:00 AM
Optimizing Outcomes in R/R ALL
r/r all
CASE
How to sequence options: case-based discussion
MD Anderson Cancer Center
Novel agents in R/R ALL
City of Hope
PRO
Debate: CAR-T as definitive therapy or bridge to allo-SCT
Memorial Sloan Kettering
CON
Debate: CAR-T as definitive therapy or bridge to allo-SCT
Moffitt Cancer Center
panel
Panel discussion
12:00 PM
Sponsor Symposium 5 · Lunch
Optimizing ALL therapy and how to sequence immunotherapies
12:45 PM
Networking Lunch
08
Session 08 · 1:30 PM
ALL Personalized Therapy
All
Genomic classification of ALL
University of Nebraska Medical Center
Myeloid mutations in ALL: a new entity
MD Anderson Cancer Center
Ph-like ALL
Children's Hospital of Philadelphia
T-cell ALL, ETP, and near-ETP
University of Rochester
panel
Panel discussion
2:30 PM
Sponsor Symposium 6
Targeting the Menin Pathway: Post-EHA Perspectives in Acute Leukemia
09
Session 09 · 3:00 PM
Optimizing Frontline AML — Uses of Venetoclax
Aml
The ideal molecular classification of frontline AML in clinical practice
MD Anderson Cancer Center
AZA-VEN in younger patients: changing the paradigm
University of Colorado School of Medicine
Improving conditioning by incorporating venetoclax pre-alloSCT
MD Anderson Cancer Center
PRO
Debate: Venetoclax-based triplet vs doublet in frontline FLT3-ITD AML, non-IC
MD Anderson Cancer Center
Con
Debate: Venetoclax-based triplet vs doublet in frontline FLT3-ITD AML, non-IC
Northwestern Medicine
panel
Panel discussion
4:15 PM
Closing Remarks · Summit Adjourns ·Dr. Naval Daver & Dr. Elias Jabbour
04 — Key Opinion Leaders
Co-Chairs & Faculty.
Co-Chair
Naval Daver, MD
MD Anderson Cancer Center
Co-Chair
Elias Jabbour, MD
MD Anderson Cancer Center
Yasmin Abaza
Northwestern Medicine
FACULTY
Yasmin Abaza
Northwestern Medicine
IN THE PROGRAM
Case
MDS case-based discussion
Session 01 · MDS Updates & Case Discussions
Hussein Abbas
MD Anderson Cancer Center
FACULTY
Hussein Abbas
MD Anderson Cancer Center
IN THE PROGRAM
Immune and inflammatory drivers of AML: therapeutic opportunities
Session 06 · Future Directions in AML Therapy
Ibrahim Aldoss
City of Hope
FACULTY
Ibrahim Aldoss
City of Hope
IN THE PROGRAM
Novel agents in R/R ALL
Session 07 · Optimizing Outcomes in R/R ALL
Sankalp Arora
Huntsman Cancer Institute
FACULTY
Sankalp Arora
Huntsman Cancer Institute
IN THE PROGRAM
Case
Case discussion: sequential targeted therapy in AML
Session 06 · Future Directions in AML Therapy
Hima Atluri
Northwestern Medicine
FACULTY
Hima Atluri
Northwestern Medicine
IN THE PROGRAM
Con
Debate: Venetoclax-based triplet vs doublet in frontline FLT3-ITD AML, non-IC
Session 09 · Optimizing Frontline AML
Prithviraj Bose
MD Anderson Cancer Center
FACULTY
Prithviraj Bose
MD Anderson Cancer Center
IN THE PROGRAM
Management of post-JAK inhibitor MF
Session 02 · MPN Updates & Case Discussions
Courtney DiNardo
MD Anderson Cancer Center
FACULTY
Courtney DiNardo
MD Anderson Cancer Center
IN THE PROGRAM
Incorporating venetoclax into frontline IC regimens: research or prime time?
Session 09 · Optimizing Frontline AML
Hannah Goulart
MD Anderson Cancer Center
FACULTY
Hannah Goulart
MD Anderson Cancer Center
IN THE PROGRAM
Case
How to sequence options: case-based discussion
Session 07 · Optimizing Outcomes in R/R ALL
Pro
Debate: Venetoclax-based triplet vs doublet in frontline FLT3-ITD AML, non-IC
Session 09 · Optimizing Frontline AML
Fadi Haddad
MD Anderson Cancer Center
FACULTY
Fadi Haddad
MD Anderson Cancer Center
IN THE PROGRAM
Case
Case presentation — MPN
Session 02 · MPN Updates & Case Discussions
Case
CML case presentation
Session 05 · Chronic Leukemia
Chris Hourigan
Fralin Biomedical Research Institute, VTC
FACULTY
Chris Hourigan
Fralin Biomedical Research Institute, VTC
IN THE PROGRAM
Using FLT3 MRD to guide treatment in FLT3-mutated AML
Session 03 · Targeted Therapies in AML
Nitin Jain
MD Anderson Cancer Center
FACULTY
Nitin Jain
MD Anderson Cancer Center
IN THE PROGRAM
How to optimize frontline therapy in CLL
Session 05 · Chronic Leukemia
Tapan Kadia
MD Anderson Cancer Center
FACULTY
Tapan Kadia
MD Anderson Cancer Center
IN THE PROGRAM
MRD as endpoint and MRD-based therapies in AML: myth or reality?
Session 06 · Future Directions in AML Therapy
Joseph Khoury
University of Nebraska Medical Center
FACULTY
Joseph Khoury
University of Nebraska Medical Center
IN THE PROGRAM
Genomic classification of ALL
Session 08 · ALL Personalized Therapy
Rami Komrokji
Moffitt Cancer Center
FACULTY
Rami Komrokji
Moffitt Cancer Center
IN THE PROGRAM
Updates in lower-risk MDS management and upcoming drugs
Session 01 · MDS Updates & Case Discussions
Andrew Kuykendall
Moffitt Cancer Center
FACULTY
Andrew Kuykendall
Moffitt Cancer Center
IN THE PROGRAM
Optimizing frontline therapy of MF
Session 02 · MPN Updates & Case Discussions
Aaron Logan
UCSF Health
FACULTY
Aaron Logan
UCSF Health
IN THE PROGRAM
How to tailor therapy according to MRD
Session 04 · Optimizing Frontline Therapy in ALL
Sanam Loghavi
MD Anderson Cancer Center
FACULTY
Sanam Loghavi
MD Anderson Cancer Center
IN THE PROGRAM
The ideal molecular classification of frontline AML in clinical practice
Session 09 · Optimizing Frontline AML
Kristen O'Dwyer
University of Rochester
FACULTY
Kristen O'Dwyer
University of Rochester
IN THE PROGRAM
T-cell ALL, ETP, and near-ETP
Session 08 · ALL Personalized Therapy
Jae Park
Jae Park
FACULTY
Jae Park
Jae Park
IN THE PROGRAM
Pro
Debate: CAR-T as definitive therapy or bridge to allo-SCT
Session 07 · Optimizing Outcomes in R/R ALL
Naveen Pemmaraju
MD Anderson Cancer Center
FACULTY
Naveen Pemmaraju
MD Anderson Cancer Center
IN THE PROGRAM
Frontline treatment options for PV and ET
Session 02 · MPN Updates & Case Discussions
Alexander Perl
Penn Medicine
FACULTY
Alexander Perl
Penn Medicine
IN THE PROGRAM
FLT3 inhibitors in AML: frontline approaches in younger and older patients
Session 03 · Targeted Therapies in AML
Daniel Pollyea
University of Colorado School of Medicine
FACULTY
Daniel Pollyea
University of Colorado School of Medicine
IN THE PROGRAM
AZA-VEN in younger patients: changing the paradigm
Session 09 · Optimizing Frontline AML
Uday Popat
MD Anderson Cancer Center
FACULTY
Uday Popat
MD Anderson Cancer Center
IN THE PROGRAM
Improving conditioning by incorporating venetoclax pre-alloSCT
Session 09 · Optimizing Frontline AML
David Sallman
Moffitt Cancer Center
FACULTY
David Sallman
Moffitt Cancer Center
IN THE PROGRAM
CD123 and CD33 targeting in AML: bench to bedside
Session 06 · Future Directions in AML Therapy
Mazyar Shadman
Fred Hutchinson Cancer Center
FACULTY
Mazyar Shadman
Fred Hutchinson Cancer Center
IN THE PROGRAM
Treatment of R/R CLL
Session 05 · Chronic Leukemia
Bijal Shah
Moffitt Cancer Center
FACULTY
Bijal Shah
Moffitt Cancer Center
IN THE PROGRAM
Con
Debate: CAR-T as definitive therapy or bridge to allo-SCT
Session 07 · Optimizing Outcomes in R/R ALL
Nicholas Short
MD Anderson Cancer Center
FACULTY
Nicholas Short
MD Anderson Cancer Center
IN THE PROGRAM
How I treat Ph-positive ALL
Session 04 · Optimizing Frontline Therapy in ALL
Mahesh Swaminathan
MD Anderson Cancer Center
FACULTY
Mahesh Swaminathan
MD Anderson Cancer Center
IN THE PROGRAM
Case
CLL case presentation
Session 05 · Chronic Leukemia
Koichi Takahashi
MD Anderson Cancer Center
FACULTY
Koichi Takahashi
MD Anderson Cancer Center
IN THE PROGRAM
No items found.
Sarah Tasian
Children's Hospital of Philadelphia
FACULTY
Sarah Tasian
Children's Hospital of Philadelphia
IN THE PROGRAM
Ph-like ALL
Session 08 · ALL Personalized Therapy
Eunice Wang
Roswell Park Comprehensive Cancer Center
FACULTY
Eunice Wang
Roswell Park Comprehensive Cancer Center
IN THE PROGRAM
Are all menin inhibitors made equal? Resistance and selection
Session 03 · Targeted Therapies in AML
Joshua Zeidner
UNC
FACULTY
Joshua Zeidner
UNC
IN THE PROGRAM
Frontline menin inhibitors: ongoing trials and data
Session 03 · Targeted Therapies in AML
Ann-Kathrin Eisfeld
The Ohio State University
FACULTY
Ann-Kathrin Eisfeld
The Ohio State University
IN THE PROGRAM
From bystander to target: the impact of RAS in AML
Session 03 · Targeted Therapies in AML
MD Anderson · Moffitt · Memorial Sloan Kettering · Fred Hutchinson · City of Hope · Penn Medicine · UCSF · Children's Hospital of Philadelphia · Roswell Park · Northwestern · University of Rochester · University of Colorado · University of Nebraska · Fralin Biomedical Research Institute (VTC) · UNC
05 — Founding Partners
Made possible by our partners.
NextGen Heme Summit is made possible by the support of the following founding partners. Their commitment advances education in hematologic malignancies.
Founding Lead Partners
Major Partners
Partners
SUPPORTERS
06 — Venue
Denver, Colorado.
Le Méridien Denver Downtown
1475 California St · 80202
Dates
Wednesday–Friday, 26–28 August 2026
Welcome reception · Wednesday 26 August, evening
Venue
Le Méridien Denver Downtown
1475 California Street, Denver, Colorado, USA, 80202
Focus
Leukemias, MDS and MPN
AML · ALL · CML · CLL
Inquiries
07 — Continuing the Conversation
Get in touch.
Next
Drug Resistance
Summit 2027
May 2027 · PENDRY Chicago
TBA
Participation is reserved for invited healthcare professionals and partners. For all registration and sponsorship inquiries, contact us at:
info@thekolnetwork.comthekolnetwork.com